瑞舒伐他汀钙与匹伐他汀钙在高脂血症应用中的成本-效果分析
|
摘要
目的:研究与分析瑞舒伐他汀钙与匹伐他汀钙在高脂血症应用中的成本-效果。方法:选取2017年2月～2018年7月140例高脂血症患者为研究对象,根据随机数字表法分为A组(瑞舒伐他汀钙组)70例和B组(匹伐他汀钙组)70例。比较两组的临床疗效(总有效率)、成本-效果比及敏感性、不良反应发生率。结果:两组临床总有效率及不良反应发生率比较,差异无统计学意义(P>0.05),A组的成本-效果比低于B组,成本-效果分析与敏感度分析一致。结论:瑞舒伐他汀钙在高脂血症应用中的成本-效果相对较好,是较好的调脂方案,应用价值相对较高。
Objective:To study and analyze the cost-effectiveness of rosuvastatin calcium and pitavastatin calcium in the application of hyperlipoidemia.Methods:140 patients with hyperlipoidemia from February 2017 to July 2018 were selected as the study object,and they were divided into group A(rosuvastatin calcium group)70 cases and group B(pitavastatin calcium group)70 cases according to the method of random number table.Then the clinical effect(total effective rates),cost-effectiveness ratio and adverse reaction rates of two groups were compared.Results:The total effective rates and adverse reaction rates of two groups were compared,the differences of two groups were no statistically significant(P >0.05),the cost-effectiveness ratio of group A was lower than that of group B,the cost-effectiveness analysis was consistent with sensitivity analysis.Conclusion:The cost-effectiveness of rosuvastatin calcium in the application of hyperlipoidemia is relatively better,and it is the better lipid-lowering plan in the application of patients with hyperlipoidemia,so its application value is relatively higher.
Objective:To study and analyze the cost-effectiveness of rosuvastatin calcium and pitavastatin calcium in the application of hyperlipoidemia.Methods:140 patients with hyperlipoidemia from February 2017 to July 2018 were selected as the study object,and they were divided into group A(rosuvastatin calcium group)70 cases and group B(pitavastatin calcium group)70 cases according to the method of random number table.Then the clinical effect(total effective rates),cost-effectiveness ratio and adverse reaction rates of two groups were compared.Results:The total effective rates and adverse reaction rates of two groups were compared,the differences of two groups were no statistically significant(P >0.05),the cost-effectiveness ratio of group A was lower than that of group B,the cost-effectiveness analysis was consistent with sensitivity analysis.Conclusion:The cost-effectiveness of rosuvastatin calcium in the application of hyperlipoidemia is relatively better,and it is the better lipid-lowering plan in the application of patients with hyperlipoidemia,so its application value is relatively higher.
引文
[1]郭胜红,汪延安,孙文武,等.两种中等强度他汀类药物方案治疗高脂血症的成本-效果分析[J].中国药房,2017,28(26):3610-3613.
[2]张小龙,沈亚兵.瑞舒伐他汀钙和阿托伐他汀钙对冠心病调脂作用的循证药物经济学评价[J].中国初级卫生保健,2018,32(8):52-54.
[3]Steven P.Dehmer,Michael V.Maciosek,Amy B.LaFrance,et al.Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention[J].Ann Fam Med,2017,15(1):23-36.
[4]Corey J Lum,Kazuma Nakagawa,Ralph V Shohet,et al.The Cost-Benefit Balance of Statins in Hawai‘i:A Moving Target[J].Hawaii J Med Public Health,2017,76(4):99-102.
[5]黄小红,石炎川,许可珍,等.辛伐他汀片和阿托伐他汀钙片治疗高胆固醇血症的系统评价及药物经济学分析[J].临床医药实践,2018,27(9):691-694.
[6]王艳群,毕泗丽.国产与进口瑞舒伐他汀治疗原发性高脂血症的药物经济学研究[J].中国医院用药评价与分析,2018,18(8):1060-1062.
[7]李裕兴,雷国大,李伟恒.3种他汀类药物治疗冠心病的成本-效果分析[J].中国医院用药评价与分析,2016,16(3):345-347.
[8]柏蓉.3种不同他汀类药物治疗高脂血症的成本-效果分析[J].中国药房,2015,26(26):3620-3622.
[9]梁宇锋,李松,韦国麟.瑞舒伐他汀和阿托伐他汀治疗动脉粥样硬化性脑梗死伴高脂血症的成本-效果分析[J].吉林医学,2015,36(18):4053-4054.
[10]王国英,田野,韩晟,等.匹伐他汀治疗高胆固醇血症的药物经济学评价[J].中国药物经济学,2017,12(4):13-17.
[11]杨迎东.瑞舒伐他汀与阿托伐他汀对老年高脂血症有效性、安全性及经济性对比[J].中国现代药物应用,2016,10(11):160-161.
[12]李莉.瑞舒伐他汀与阿托伐他汀在冠心病调脂治疗中的药物经济学比较[J].海峡药学,2015,27(10):271-273.
[13]周琴,李正茂.国产瑞舒伐他汀与进口阿托伐他汀在PCI术后患者应用中疗效与经济学比较[J].蚌埠医学院学报,2016,41(12):1659-1662.
[2]张小龙,沈亚兵.瑞舒伐他汀钙和阿托伐他汀钙对冠心病调脂作用的循证药物经济学评价[J].中国初级卫生保健,2018,32(8):52-54.
[3]Steven P.Dehmer,Michael V.Maciosek,Amy B.LaFrance,et al.Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention[J].Ann Fam Med,2017,15(1):23-36.
[4]Corey J Lum,Kazuma Nakagawa,Ralph V Shohet,et al.The Cost-Benefit Balance of Statins in Hawai‘i:A Moving Target[J].Hawaii J Med Public Health,2017,76(4):99-102.
[5]黄小红,石炎川,许可珍,等.辛伐他汀片和阿托伐他汀钙片治疗高胆固醇血症的系统评价及药物经济学分析[J].临床医药实践,2018,27(9):691-694.
[6]王艳群,毕泗丽.国产与进口瑞舒伐他汀治疗原发性高脂血症的药物经济学研究[J].中国医院用药评价与分析,2018,18(8):1060-1062.
[7]李裕兴,雷国大,李伟恒.3种他汀类药物治疗冠心病的成本-效果分析[J].中国医院用药评价与分析,2016,16(3):345-347.
[8]柏蓉.3种不同他汀类药物治疗高脂血症的成本-效果分析[J].中国药房,2015,26(26):3620-3622.
[9]梁宇锋,李松,韦国麟.瑞舒伐他汀和阿托伐他汀治疗动脉粥样硬化性脑梗死伴高脂血症的成本-效果分析[J].吉林医学,2015,36(18):4053-4054.
[10]王国英,田野,韩晟,等.匹伐他汀治疗高胆固醇血症的药物经济学评价[J].中国药物经济学,2017,12(4):13-17.
[11]杨迎东.瑞舒伐他汀与阿托伐他汀对老年高脂血症有效性、安全性及经济性对比[J].中国现代药物应用,2016,10(11):160-161.
[12]李莉.瑞舒伐他汀与阿托伐他汀在冠心病调脂治疗中的药物经济学比较[J].海峡药学,2015,27(10):271-273.
[13]周琴,李正茂.国产瑞舒伐他汀与进口阿托伐他汀在PCI术后患者应用中疗效与经济学比较[J].蚌埠医学院学报,2016,41(12):1659-1662.